KIDS OrthoPediatrics Corp

OrthoPediatrics Corp. Announces First PNP|FEMUR Case Performed in the United Kingdom

OrthoPediatrics Corp. Announces First PNP|FEMUR Case Performed in the United Kingdom

WARSAW, Ind., Dec. 29, 2020 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics”) (NASDAQ: KIDS), a company exclusively focused on advancing the field of pediatric orthopedics, today announced the first surgery in the United Kingdom utilizing the new Pediatric Nailing Platform | FEMUR (“PNP|FEMUR”).

Representing a significant new option for certain anatomies, the PNP|FEMUR system is designed for use in pediatric and small stature adult patients to address femoral fractures or deformity correction procedures. The system launched in the United States in 2018 and is available in the U.K. markets as of this month.

The first case was performed at Sheffield Children’s Hospital by James Fernandes, Consultant Orthopaedic Surgeon. Mr. Fernandes commented, “The new PNP nail is quite advanced and versatile with interesting newer instrumentation elements that will be very handy to the surgeon, especially with difficult and complex cases.”

Joe Hauser, OrthoPediatrics’ Senior Vice President of Trauma & Deformity Correction, stated, “We are extremely pleased to introduce the PNP|FEMUR system to surgeons in the U.K. Our commitment to continuous improvement and innovation in pediatric orthopedics is best represented in the launch of our 3rd generation nailing system, which was built on the shoulders of the original PediNail from over 8 years and 6,000+ cases of global surgeon feedback and experience. This new system has graduated to treat unique pediatric and adolescent anatomies and we are delighted to hear the first case in the U.K. was a great success! We look forward to helping many more children with this technology.”

About OrthoPediatrics Corp.

Founded in 2006, OrthoPediatrics is an orthopedic company focused exclusively on advancing the field of pediatric orthopedics. As such it has developed the most comprehensive product offering to the pediatric orthopedic market to improve the lives of children with orthopedic conditions. OrthoPediatrics currently markets 35 surgical systems that serve three of the largest categories within the pediatric orthopedic market. This product offering spans trauma and deformity, scoliosis, and sports medicine/other procedures. OrthoPediatrics’ global sales organization is focused exclusively on pediatric orthopedics and distributes its products in the United States and 43 countries outside the United States. For more information, please visit .

Investor Contact

The Ruth Group

Jan Medina, CFA

(646) 536-7035

 



EN
29/12/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on OrthoPediatrics Corp

 PRESS RELEASE

OrthoPediatrics to Participate in Upcoming Conferences

OrthoPediatrics to Participate in Upcoming Conferences WARSAW, Ind., Nov. 04, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, a company focused exclusively on advancing the field of pediatric orthopedics, today announced that it will participate in three upcoming investor conferences. Event: Stifel 2025 Healthcare Conference Format: Fireside Chat Date: Thursday, November 13, 2025Time: 1:20 pm ET Event: Jeffries Global Healthcare Conference in LondonFormat: P...

 PRESS RELEASE

OrthoPediatrics Corp. Reports Third Quarter 2025 Financial Results

OrthoPediatrics Corp. Reports Third Quarter 2025 Financial Results Increased Third Quarter 2025 Revenue 12% Year-over-year, and Increased Adjusted EBITDA by 56% year-over-year WARSAW, Ind., Oct. 28, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced its financial results for the third quarter ended September 30, 2025. Third Quarter 2025 and Recent Business Highlights       Helped over 37,000 children in the third quarter of 2025 and approximat...

 PRESS RELEASE

OrthoPediatrics Corp. Receives FDA approval for 3P™ Pediatric Plating ...

OrthoPediatrics Corp. Receives FDA approval for 3P™ Pediatric Plating Platform™ Small-Mini System, the second of several systems in the 3P family WARSAW, Ind., Oct. 28, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced the FDA approval of its 3P™ Pediatric Plating Platform™ Small-Mini System, the second of several systems in the 3P family. This represents the company’s 6th FDA approval in 2025. The 3P Small-Mini System is a versatile plate and s...

 PRESS RELEASE

OrthoPediatrics Corp. to Report Third Quarter Financial Results on Oct...

OrthoPediatrics Corp. to Report Third Quarter Financial Results on October 28, 2025 WARSAW, Ind., Oct. 15, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced that the Company is scheduled to release its third quarter 2025 financial results on October 28, 2025 after the market closes. OrthoPediatrics will host a conference call on Tuesday, October 28, 2025 at 4:30 p.m. ET to discuss the results. Investors interested in listening to the conference ...

 PRESS RELEASE

OrthoPediatrics Corp. Announces Preliminary Third Quarter 2025 Revenue...

OrthoPediatrics Corp. Announces Preliminary Third Quarter 2025 Revenue and Revised 2025 Guidance Company to host conference call today, October 9th, 2025, to discuss the financial results and updated outlook WARSAW, Ind., Oct. 09, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced preliminary unaudited financial highlights for the third quarter ended September 30, 2025, and revised 2025 financial guidance. Preliminary Third Quarter 2025 Results...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch